Centessa Pharmaceuticals plc
CNTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $7 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $7 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $150 | $124 | $155 | $96 |
| G&A Expenses | $51 | $54 | $55 | $43 |
| SG&A Expenses | $51 | $54 | $55 | $43 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2 | $236 |
| Operating Expenses | $201 | $178 | $212 | $375 |
| Operating Income | -$201 | -$171 | -$212 | -$375 |
| % Margin | – | -2,499.4% | – | – |
| Other Income/Exp. Net | -$32 | -$5 | -$5 | -$7 |
| Pre-Tax Income | -$233 | -$176 | -$217 | -$382 |
| Tax Expense | $3 | -$25 | -$1 | $0 |
| Net Income | -$236 | -$151 | -$216 | -$382 |
| % Margin | – | -2,204.7% | – | – |
| EPS | -2.06 | -1.57 | -2.31 | -4.24 |
| % Growth | -31.2% | 32% | 45.5% | – |
| EPS Diluted | -2.06 | -1.57 | -2.31 | -4.24 |
| Weighted Avg Shares Out | 114 | 96 | 93 | 90 |
| Weighted Avg Shares Out Dil | 114 | 96 | 93 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $10 | $0 | $0 |
| Interest Expense | $10 | $10 | $7 | $3 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$222 | -$165 | -$210 | -$139 |
| % Margin | – | -2,413.9% | – | – |